Boumber Y et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 2012;26(11):2428-31. Abstract
Buyse M et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011;117(26):7007-13. Abstract
Feldman EJ et al. First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011;29(8):979-85. Abstract
Garcia-Manero G et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia 2016;30(4):889-96. Abstract
Garcia-Manero G et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29(18):2521-7. Abstract
Goldstone AH et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98(5):1302-11. Abstract
Lancet JE et al. Five-year final results of a phase III study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. ASCO 2020;Abstract 7510.
Lancet JE et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract
Lancet JE et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123(21):3239-46. Abstract
Li LH et al. Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Res 1970;30(11):2770-5. Abstract
Lim WS et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Res 2010;51(8):1536-42. Abstract
Lindsley RC et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015;125(9):1367-76. Abstract
Ostgard LSG et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol 2015;33(31):3641-9. Abstract
Tolcher AW, Mayer LD. Improving combination cancer therapy: The CombiPlex® development platform. Future Oncol 2018;14(13):1318-32. Abstract
Wei AH et al. The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. ASH 2019;Abstract LBA-3.